Pulmonary Infections

  • Jonathan E. Rodnick
  • James Gude
Chapter

Abstract

Pneumonia is a parenchymal lung infection that usually shows as an infiltrate on chest films, except in those with severe dehydration or in the patient with acquired immunodeficiency syndrome (AIDS).1 Incidence is highest in the young (less than 5 years) and old (especially nursing home residents). With about 60,000 deaths yearly, pneumonia is the sixth leading cause of deaths. There are an estimated 4 million cases of pneumonia in the United States yearly, with up to 600,000 hospital admissions.2 For the family physician, pneumonia ranks as the 25th most common problem seen and accounts for 0.8% of office visits. A family physician with 2000 patients would see, on the average, 25 to 30 patients each year with pneumonia. About 20% of outpatient pneumonia patients require admission to the hospital, but most of the epidemiologic data on pneumonias are from inpatients. There are few controlled clinical trials on outpatient pneumonia treatments.

Keywords

Chronic Obstructive Pulmonary Disease Chest Radiograph Mycoplasma Pneumoniae Directly Observe Therapy Bacille Calmette Guerin 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Opravil M, Marincek B, Fuchs WA, et al. Shortcomings of chest radiography in detecting Pneumocystis carinii pneumonia. J Acquir Immune Defic Syndr 1994;7:39–45.PubMedGoogle Scholar
  2. 2.
    Garibaldi RA. Epidemiology of community-acquired respiratory tract infections in adults: incidence, etiology, and impact. Am J Med 1985;78:32–7.PubMedCrossRefGoogle Scholar
  3. 3.
    Mundy LM, Auawaeter PG, Oldach D, et al. Community-acquired pneumonia: impact of immune status. Am J Respir Crit Care 1995;152:1309–15.CrossRefGoogle Scholar
  4. 4.
    British Thoracic Society Research Committee. Community-acquired pneumonia in adults in British hospitals in 1982–1983: a survey of aetiology, mortality, prognostic factors and outcomes. Q J Med 1987;62:195–220.Google Scholar
  5. 5.
    Peters CJ, Khan AS, Zaki SR. Hanta viruses in the United States. Arch Intern Med 1996;156:705–7.PubMedCrossRefGoogle Scholar
  6. 6.
    Fine MJ, Smith DJ, Singer DE. Hospitalization decision in patients with community-acquired pneumonia: a prospective cohort study Am J Med 1990;89:713–21.Google Scholar
  7. 7.
    Farr BM, Sloman AJ, Fish MJ. Predicting death in patients hospitalized for community-acquired pneumonia. Ann Intern Med 1991;115:428–36.PubMedCrossRefGoogle Scholar
  8. 8.
    Bartlett JG, Mundy LM. Community-acquired pneumonia. N Engl J Med 1995;333:1618–24.PubMedCrossRefGoogle Scholar
  9. 9.
    American Thoracic Society. Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. Am Rev Respir Dis 1993;148:1418–26.CrossRefGoogle Scholar
  10. 10.
    Austrain R. Confronting drug-resistant pneumococci. Ann Intern Med 1994;121:807–9.CrossRefGoogle Scholar
  11. 11.
    Centers for Disease Control and Prevention. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1996;45:1–31.Google Scholar
  12. 12.
    Steinhoff MC, Auerbach BS, Nelson MD, et al. Antibody responses to Haemophilus influenza type B vaccines in men with human immunodeficiency virus infection. N Engl J Med 1991;325:1837–42.PubMedCrossRefGoogle Scholar
  13. 13.
    Block S, Hedrick J, Hammerschlag MR, et al. Mycoplasma pneumoniae and Chlamydia pneumoniae in pediatric community-acquired pneumonia: comparative efficacy and safety of clarithromycin vs. erythromycin ethylsuccinate. Pediatr J Infect Dis 1995;14:471–7.CrossRefGoogle Scholar
  14. 14.
    Mansel JR, Rosenow EC, Smith TF, Martin JW. Mycoplasma pneumoniae pneumonia. Chest 1989;95:639–46.PubMedCrossRefGoogle Scholar
  15. 15.
    Grayston JT. Chlamydia pneumoniae, strain TWAR. Chest 1989;95:664–8.PubMedCrossRefGoogle Scholar
  16. 16.
    Atmar RL, Greenberg SB. Pneumonia caused by Mycoplasma pneumoniae and the TWAR agent. Semin Respir Infect 1989; 4:19–31.PubMedGoogle Scholar
  17. 17.
    Jacobs E. Serological diagnosis of Mycoplasma pneumoniae infections: a critical review of current procedures. Clin Infect Dis 1993;17 Suppl:S79–82.CrossRefGoogle Scholar
  18. 18.
    Cunha BA, Ortega AM. Atypical pneumonia. Postgrad Med 1966;99:123–32.Google Scholar
  19. 19.
    Davis GS, Winn WC. Legionnaire’s disease: respiratory infections caused by Legionella bacteria. Clin Chest Med 1987;8: 419–39.PubMedGoogle Scholar
  20. 20.
    Fang G, Fine M, Orloff J, et al. New and emerging etiologies for community-acquired pneumonia with implications for therapy. Medicine (Baltimore) 1990;69:307–16.Google Scholar
  21. 21.
    Lieberman D, Porath A, Schlaeffer F, et al. Legionella species community-acquired pneumonia. Chest 1996;109:1243–9.PubMedCrossRefGoogle Scholar
  22. 22.
    Keys TF. Therapeutic considerations in the treatment of Legionella infections. Semin Respir Infect 1987;2:270–3.PubMedGoogle Scholar
  23. 23.
    Saag MS, Dismukes WE. Treatment of histoplasmosis and blastomycosis. Chest 1988;93:849–51.CrossRefGoogle Scholar
  24. 24.
    Bradsher RW. Histoplasmosis and blastomycosis. Clin Infect Dis 1996;22:5102–11.CrossRefGoogle Scholar
  25. 25.
    Stevens DA. Coccidioidomycosis. N Engl J Med 1995;332: 1077–82.PubMedCrossRefGoogle Scholar
  26. 26.
    American Thoracic Society. Treatment of tuberculosis and tuberculosis infection in adults and children. Am J Respir Crit Care Med 1994;149:1359–74.CrossRefGoogle Scholar
  27. 27.
    American Thoracic Society. Control of tuberculosis in the United States. Am Rev Respir Dis 1993;329:784–91.Google Scholar
  28. 28.
    Centers for Disease Control and Prevention. Essential components of a tuberculosis prevention and control program: recommendations of the advisory committee for the elimination of tuberculosis. MMWR 1995;44(RR-11):1–34.Google Scholar
  29. 29.
    Centers for Disease Control. The role of BCG in the prevention and control of tuberculosis in the United States. MMWR 1996;45(RR-4):1–18.Google Scholar
  30. 30.
    Currier J. Progress report: prophylaxis and therapy for MAC. AIDS Care 1996;8:45–8.Google Scholar
  31. 31.
    Goldschimdt RH, Dong BJ. Treatment of AIDS and HIV-re-lated conditions—1996. J Am Board Fam Pract 1996;9:125–48.Google Scholar
  32. 32.
    Ioannidis JP, Cappeleri JC, Skolnick PR, et al. Meta-analysis of the relative efficacy and toxicity of Pneumocystis carinii prophylactic regimens. Arch Intern Med 1966;156:177–88.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1998

Authors and Affiliations

  • Jonathan E. Rodnick
  • James Gude

There are no affiliations available

Personalised recommendations